Nat Med:细胞“对话”帮助开发糖尿病新疗法

2015-06-18 佚名 生物谷

有时候倾听对话或许可以让我们获取更多的信息,近日一篇刊登于国际杂志Nature Medicine上的研究论文中,来自加州大学戴维斯分校的研究人员通过研究表示,细胞间的交谈或可控制机体对糖类的反应,理解这种细胞间的交流或可帮助我们理解糖尿病的发病机理,并且帮助开发治疗糖尿病的新型疗法。 研究者表示,他们在胰腺细胞间鉴别出了一种关键的“对话”,即一种名为尿皮素3的激素,尿皮素3可以同胰岛素一同释

有时候倾听对话或许可以让我们获取更多的信息,近日一篇刊登于国际杂志Nature Medicine上的研究论文中,来自加州大学戴维斯分校的研究人员通过研究表示,细胞间的交谈或可控制机体对糖类的反应,理解这种细胞间的交流或可帮助我们理解糖尿病的发病机理,并且帮助开发治疗糖尿病的新型疗法。

研究者表示,他们在胰腺细胞间鉴别出了一种关键的“对话”,即一种名为尿皮素3的激素,尿皮素3可以同胰岛素一同释放,同时其还会减弱胰岛素的产生,Huising教授说道,在胰岛小岛中存在很多细胞间的交谈,其可以平衡胰岛素和胰高血糖素的分泌,而尿皮素3所提供的负反馈效应对于严格控制血糖的水平非常关键。

糖尿病每年影响着数百万人的健康,当机体失去调节血糖的能力就会引发1型和2型糖尿病的发生,1型糖尿病被认为是胰岛素依赖型糖尿病,而2型糖尿病则被认为是成年型糖尿病。糖尿病往往和胰岛中的小岛结构密切相关,在小岛中β细胞会产生胰岛素;增加机体血糖会刺激胰岛素的产生,从而促进机体对糖类的循环。

小岛中同时还包含有α细胞,其会制造 ,胰高血糖素可以释放更多的葡萄糖进入血液;研究者表示,尿皮素3最开始被认为是一种和大脑发起压力反应的信号相关的激素,尿皮素3由小岛β细胞产生储存,并且同胰岛素一起被释放;在一系列实验中研究者阐明,尿皮素3可以促进小岛中名为δ细胞的细胞产生,δ细胞会释放促生长素抑制素,其会降低胰岛素的产生。

文章中研究者发现,尿皮素3在糖尿病动物模型以及糖尿病患者的β细胞中会明显减少,如果没有尿皮素3,胰腺小岛就会产生更多的胰岛素,但同时却会失去控制胰岛素的释放;通过理解不同细胞及系统之间相互交流调节血糖的机制或可帮助研究者进一步研究人类糖尿病的发病机理,同时为开发新型糖尿病疗法或带来巨大帮助。

原始出处:

Meulen TV1, Donaldson CJ2, Cáceres E2, Hunter AE1, Cowing-Zitron C3, Pound LD4, Adams MW5, Zembrzycki A6, Grove KL4, Huising MO7.Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion.Nat Med. 2015 Jun 15. doi: 10.1038/nm.3872. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-12-24 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    !!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1880697, encodeId=805c188069e82, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 24 13:28:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29223, encodeId=ff6829223fd, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28459, encodeId=2cb02845984, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28461, encodeId=f14a28461fe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:35:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554451, encodeId=10d9155445103, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606525, encodeId=d1db160652592, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 20 00:28:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]

相关资讯

Islets:科学家发现特殊基因可重新激活产胰岛素β细胞表达

近日,刊登在国际杂志Islets上的一篇研究论文中,来自博里汉姆扬大学的研究人员通过研究发现,一种特殊基因或可帮助阐明糖尿病发病的根源;目前在全球范围内高血糖影响着4亿人的健康,为了深入研究这种特殊基因的功能,研究人员转向了对患糖尿病的学生进行研究。 文章中研究者对4名患有1型糖尿病的学生进行研究,学生患病和饮食及生活方式均无关联,研究者Tessem说道,这项研究中我们调查了可以激活胰岛β细

你得前驱糖尿病了吗?

研究人员认为发展成2型糖尿病之前,存在一个前驱糖尿病,这时候的血糖水平处于“灰色地带”,高于正常值但低于糖尿病的血糖值。根据美国疾病预防与控制中心的介绍,大约三个美国成年人中就有一个处于前驱糖尿病,但只有11%左右的人意识到他们的病情。前驱糖尿病是一个很严重的问题,因为许多糖尿病的发病过程——包括神经损伤,眼部问题和心脏病等,在糖尿病还没有被诊断出来的时候就已经开始在我们的体内酝酿了。如果不对其进

FDA 2015:勃林格-礼来糖尿病复方新药Synjardy显著改善2型糖尿病血糖控制

勃林格殷格翰-礼来糖尿病联盟近日在第75届美国糖尿病协会(ADA)年会(6月5日-6月9日)上公布了实验性糖尿病新药empagliflozin一项III期临床试验的数据。该研究为期24周,在1364例2型糖尿病(T2D)患者中开展,调查了empagliflozin与二甲双胍联合疗法相对于empagliflozin单药或二甲双胍单药的疗效和安全性。主要终点是第24周糖化血红蛋白(HbA1c)从基线的

Cell Metab:靶向作用炎症有效抵御肥胖疾病

肥胖是引发很多疾病的风险因子,比如糖尿病、肝硬化以及慢性肾脏疾病等,脂肪炎症似乎是肥胖相关疾病的共同特性;近日来自都柏林大学的研究人员通过研究发现,机体中的一种特殊分子或可通过减缓逆转脂肪炎症来保护机体抵御肥胖相关疾病的发生,相关研究刊登于国际杂志Cell Metabolism上,该研究或为后期开发治疗肥胖及其相关病症的疗法提供希望。 炎症是机体对损伤的一部分天然反应,而脂氧素是一种帮助机体清除

ADA 2015:Banting奖解读-脂肪的生理功能及糖尿病药物开发靶点

Banting科学成就奖章是美国糖尿病协会科学年会的最高科学奖项,是以胰岛素发现者Banting的名字命名的。2015年在波士顿召开的第75届ADA科学年会上,Banting奖章颁给了来自德克萨斯大学西南医学中心Touchstone糖尿病研究中心主任Philipp Scherer博士。他是德克萨斯大学西南医学中心第四位获此殊荣的科学家,西南医学中心也曾诞生过6位诺贝尔奖获得者。Scherer博士多

Mol Cell Endocrinol :弱骨强代谢——指向糖尿病的新治疗

骨骼脆弱显然不是一件好事,不过科学家们怀疑,基因工程小鼠的骨骼和身体的其余部分之间的某处联系中,可能隐藏了一个答案,能够帮助肥胖者避免一些由肥胖带来的健康困扰。佐治亚大学医学院的研究人员最近报告说,拥有脆弱骨骼的小鼠有很强的代谢能力,即使是在高脂肪饮食条件下。这篇研究发表在最近的Molecular and Cellular Endocrinology杂志。 McGee-Lawrence博士是该研